Pure Global
NCT06043700

A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology

A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology
Eisai Limited·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Alzheimer's Disease
Drug/Device/Intervention
No Intervention
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Eisai Limited
Funder
Eisai Inc.
Location
Lady Lake,Orlando, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 12, 2023
End date
Mar 31, 2025
Enrollment
2000 participants
Primary outcome

Number of Participants With Low, Medium, and High Amyloid Pathology

Summary

The primary purpose of this study is to identify participants with or without symptoms of
 Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based
 biomarkers.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06043700
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06043700 through Pure Global AI's free database. This phase not specified trial is sponsored by Eisai Limited and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.